PacBio Announces Q3 Earnings Per Share of 13 Cents, Below Consensus Estimate of 14 Cents
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Q3 Revenue Performance: The company reported Q3 revenue of $38.44 million, slightly below the consensus estimate of $40.25 million.
Record Consumable Revenue: Despite the revenue shortfall, the company achieved an all-time record for consumable revenue, expanded gross margins, and reduced operating expenses.
Technological Milestone: The introduction of SPRQ-Nx chemistry marks a significant milestone in the company's technology roadmap, aimed at lowering the cost of human genome sequencing.
Commitment to Growth: The CEO emphasized the company's focus on disciplined growth and making PacBio's long-read sequencing technology more accessible globally.
Analyst Views on PACB
Wall Street analysts forecast PACB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PACB is 2.40 USD with a low forecast of 2.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 2.520
Low
2.00
Averages
2.40
High
3.00
Current: 2.520
Low
2.00
Averages
2.40
High
3.00
About PACB
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
